Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

0H22

Bioinvent International Ab (0H22)

Bioinvent International Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0H22
DateTimeSourceHeadlineSymbolCompany
04/29/20214:52AMPR Newswire (US)Resolutions at BioInvent's Annual General Meeting 2021LSE:0H22Bioinvent International Ab
04/29/20214:49AMPR Newswire (US)Resolutions at BioInvent's Annual General Meeting 2021LSE:0H22Bioinvent International Ab
04/12/202112:44AMPR Newswire (US)BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancerLSE:0H22Bioinvent International Ab
04/12/202112:41AMPR Newswire (US)BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancerLSE:0H22Bioinvent International Ab
04/08/20211:53AMPR Newswire (US)BioInvent International's Annual Report 2020 publishedLSE:0H22Bioinvent International Ab
04/08/20211:50AMPR Newswire (US)BioInvent International's Annual Report 2020 publishedLSE:0H22Bioinvent International Ab
03/31/20211:50AMPR Newswire (US)Change in the number of shares and votes in BioInvent International ABLSE:0H22Bioinvent International Ab
03/31/20211:48AMPR Newswire (US)Change in the number of shares and votes in BioInvent International ABLSE:0H22Bioinvent International Ab
02/23/20212:22AMPR Newswire (US)BioInvent International Financial Statement January 1 - December 31, 2020LSE:0H22Bioinvent International Ab
02/23/20212:21AMPR Newswire (US)BioInvent International Financial Statement January 1 - December 31, 2020LSE:0H22Bioinvent International Ab
12/09/20202:15AMPR Newswire (US)Nomination Committee appointed for BioInvent International's Annual General Meeting 2021LSE:0H22Bioinvent International Ab
12/09/20202:09AMPR Newswire (US)Nomination Committee appointed for BioInvent International's Annual General Meeting 2021LSE:0H22Bioinvent International Ab
12/07/20201:44AMPR Newswire (US)Record date for reverse share split in BioInvent International determinedLSE:0H22Bioinvent International Ab
12/07/20201:42AMPR Newswire (US)Record date for reverse share split in BioInvent International determinedLSE:0H22Bioinvent International Ab
11/27/20204:44AMPR Newswire (US)Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020LSE:0H22Bioinvent International Ab
11/27/20204:42AMPR Newswire (US)Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020LSE:0H22Bioinvent International Ab
10/29/20202:17AMPR Newswire (US)BioInvent Interim Report January 1 - September 30, 2020LSE:0H22Bioinvent International Ab
10/29/20202:15AMPR Newswire (US)BioInvent Interim Report January 1 - September 30, 2020LSE:0H22Bioinvent International Ab
08/27/20201:18AMPR Newswire (US)BioInvent Interim Report January 1 - June 30, 2020LSE:0H22Bioinvent International Ab
08/27/20201:16AMPR Newswire (US)BioInvent Interim Report January 1 - June 30, 2020LSE:0H22Bioinvent International Ab
06/18/20208:21AMPR Newswire (US)Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020LSE:0H22Bioinvent International Ab
06/18/20208:18AMPR Newswire (US)Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020LSE:0H22Bioinvent International Ab
04/28/20201:17AMPR Newswire (US)BioInvent Interim Report January 1 - March 31, 2020LSE:0H22Bioinvent International Ab
04/28/20201:15AMPR Newswire (US)BioInvent Interim Report January 1 - March 31, 2020LSE:0H22Bioinvent International Ab
02/27/202012:54AMPR Newswire (US)BioInvent Financial Statement January 1 - December 31, 2019LSE:0H22Bioinvent International Ab
02/27/202012:52AMPR Newswire (US)BioInvent Financial Statement January 1 - December 31, 2019LSE:0H22Bioinvent International Ab
08/22/20191:47AMPR Newswire (US)BioInvent: Interim Report January 1 - June 30, 2019LSE:0H22Bioinvent International Ab
08/22/20191:44AMPR Newswire (US)BioInvent: Interim Report January 1 - June 30, 2019LSE:0H22Bioinvent International Ab
08/20/20193:54AMPR Newswire (US)BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Com...LSE:0H22Bioinvent International Ab
08/20/20193:52AMPR Newswire (US)BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Com...LSE:0H22Bioinvent International Ab
 Showing the most relevant articles for your search:LSE:0H22